Loading...
XNASPYPD
Market cap20mUSD
Dec 24, Last price  
2.97USD
1D
-19.29%
1Q
-17.96%
IPO
-99.48%
Name

PolyPid Ltd

Chart & Performance

D1W1MN
XNAS:PYPD chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
25.94%
Rev. gr., 5y
%
Revenues
0k
Net income
-24m
L-39.62%
-1,790,000-3,884,000-8,220,000-11,392,000-54,488,0005,917,0004,750,000-35,324,000-40,713,000-39,525,000-23,865,000
CFO
-17m
L-49.77%
-1,857,000-2,518,0000-9,733,000-12,312,000-16,678,000-17,358,000-21,596,000-32,386,000-34,317,000-17,236,000
Earnings
Feb 12, 2025

Profile

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
IPO date
Jun 26, 2020
Employees
57
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
17,970
40,609
43,993
Unusual Expense (Income)
NOPBT
(17,970)
(40,609)
(43,993)
NOPBT Margin
Operating Taxes
69
97
(1,618)
Tax Rate
NOPAT
(18,039)
(40,706)
(42,375)
Net income
(23,865)
-39.62%
(39,525)
-2.92%
(40,713)
15.26%
Dividends
Dividend yield
Proceeds from repurchase of equity
8,723
4,423
1,034
BB yield
-163.46%
-32.64%
-0.96%
Debt
Debt current
4,543
4,983
Long-term debt
8,633
10,879
Deferred revenue
2,548
2,548
Other long-term liabilities
398
174
199
Net debt
7,567
3,268
(32,443)
Cash flow
Cash from operating activities
(17,236)
(34,317)
(32,386)
CAPEX
(196)
(1,767)
(2,993)
Cash from investing activities
3,804
16,575
36,900
Cash from financing activities
9,976
16,428
1,034
FCF
(15,579)
(43,623)
(45,004)
Balance
Cash
5,609
12,594
32,203
Long term investments
240
Excess cash
5,609
12,594
32,443
Stockholders' equity
(238,309)
(214,412)
(174,617)
Invested Capital
250,938
236,717
211,046
ROIC
ROCE
EV
Common stock shares outstanding
1,404
648
624
Price
3.80
-81.84%
20.93
-87.85%
172.20
-42.02%
Market cap
5,337
-60.62%
13,550
-87.39%
107,461
13.28%
EV
12,904
16,818
75,018
EBITDA
(16,148)
(38,888)
(42,875)
EV/EBITDA
Interest
1,711
1,023
Interest/NOPBT